RBC Capital Maintains Outperform on Ambrx Biopharma, Raises Price Target to $33
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has maintained an Outperform rating on Ambrx Biopharma (NASDAQ:AMAM) and raised the price target from $29 to $33.
October 23, 2023 | 2:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has maintained an Outperform rating on Ambrx Biopharma and raised the price target from $29 to $33, which could positively impact the stock's performance.
The Outperform rating maintained by RBC Capital indicates that they expect Ambrx Biopharma to outperform the market. The increase in the price target from $29 to $33 suggests that they believe the stock has potential for further growth. This could lead to increased investor confidence and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100